We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Molecular Testing Software Reduces Time to qPCR-Based Diagnostic Results by Over Two Hours

By LabMedica International staff writers
Posted on 14 Jul 2023

Clinical laboratories and kit producers specializing in molecular diagnostics often struggle with outdated systems that are challenging to scale up for increased workload or diversified testing offerings. More...

Additionally, cumbersome and inefficient procedures may hinder sample tracking and compliance maintenance, which are crucial for molecular diagnostic labs. For assay developers, shifts between developmental stages and the absence of process standardization can slow down market readiness and risk regulatory compliance. Now, a new scalable software designed to address challenges with error-prone, manual molecular testing workflows helps streamline routine diagnostics testing for standardization and faster time-to-results.

Thermo Fisher Scientific (Waltham, MA, USA) has introduced Diomni Enterprise Software which enhances a lab's adaptability to the rapidly evolving testing requirements by integrating workflow steps within a single interface. This solution is suitable for a wide range of labs that perform regular quantitative polymerase chain reaction (qPCR) diagnostic tests, as well as developers aiming to expedite the development of novel testing solutions. Diomni Enterprise seamlessly connects the individual steps of the workflow into a single integrated platform, thus improving the productivity of qPCR workflows.

Diomni Enterprise enables labs to function at maximum efficiency by automating the interface with existing laboratory information systems (LIS), thus boosting efficiency and traceability. By consolidating labs, instruments, assays, and LIS within one system, the software enhances traceability, facilitating sample and reagent tracking throughout the sample's journey. It also allows multiple users to simultaneously access assay templates and results. Diomni Enterprise supports a diverse range of testing workflows and is compatible with both research-use-only and in vitro diagnostic assays and instruments.

“During the pandemic, we worked to quickly launch a digital solution that would allow clinical labs to continue operations, taking into account the dramatic changes in the PCR testing landscape,” said Fernando Beils, vice president, general manager of qPCR instruments, Thermo Fisher Scientific. “What followed was the earliest stages of the Diomni solution, delivering a digital platform that supports testing workflows with the flexibility required to accommodate rapidly evolving needs. We have continued to build on this platform and are excited to deliver a more robust and scalable tool for labs and assay developers across testing environments.”

Related Links:
Thermo Fisher Scientific


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.